References
- Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20
- Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12
- James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016;387:1163-77
- Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373:737-46
- Templeton AJ, Vera-Badillo FE, Wang L, et al. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol 2013;24:2972-7
- 2016 ASP Drug Pricing Files. Centers for Medicare and Medicaid Services, 2015. Baltimore, MD: ASP Drug Pricing Files, https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2016ASPFiles.html. [Last accessed February 12, 2016]
- Alemayehu B, Buysman E, Parry D, et al. Economic burden and healthcare utilization associated with castration-resistant prostate cancer in a commercial and Medicare Advantage US patient population. J Med Econ 2010;13:351-61
- Mehra M, Wu Y, Dhawan R. Healthcare resource use in advanced prostate cancer patients treated with docetaxel. J Med Econ 2012;15:836-43
- Newcomer LN, Gould B, Page RD, et al. Changing physician incentives for affordable, quality cancer care: results of an episode payment model. J Oncol Pract 2014;10:322-6
- FFS Trends 2015. Centers for Medicare and Medicaid Services, 2016. Baltimore, MD: Centers for Medicare and Medicaid Services, https://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/FFS-Trends.html. [Last accessed February 12, 2016]
- Medicare Part B Drug Average Sales Price. Centers for Medicare and Medicaid Services, 2015. London, EC2R 8DU UK: Centers for Medicare and Medicaid Services, https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/index.html. [Last accessed February 12, 2016]
- Milliman Health Cost Guidelines. Milliman I, 2016. Alexandria, VA: Milliman Health Cost Guidelines, http://uk.milliman.com/uploadedFiles/Solutions/Products/Resources/Health_Cost_Guidelines/hcg_commercial.pdf. [Last accessed April 21, 2016]
- Grabner M, Onukwugha E, Jain R, et al. Racial variation in the cost-effectiveness of chemotherapy for prostate cancer. J Oncol Pract 2011;7:e16s-e24s
- Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424-33
- Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-48
- Sheikh NA, Petrylak D, Kantoff PW, et al. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother 2013;62:137-47